Bosentan ameliorated exercise-induced pulmonary arterial hypertension complicated with systemic sclerosis

Intern Med. 2010;49(21):2309-12. doi: 10.2169/internalmedicine.49.3812. Epub 2010 Nov 1.


Pulmonary arterial hypertension (PAH) is a frequent complication in patients with systemic sclerosis. Bosentan is used in patients with symptomatic PAH; however, it has not been established whether or not bosentan ameliorates the progression of PAH in patients with no PAH-related symptoms. We present a case of systemic sclerosis with no PAH-related symptoms in which bosentan ameliorated exercise-induced PAH evaluated by 6-minute walk stress echocardiography, brachial flow-mediated dilation, and skin temperature of hands and feet. The results suggest that administration of bosentan in patients with early-stage PAH ameliorates pulmonary arterial vasodilatation through improvement of endothelial function.

Publication types

  • Case Reports

MeSH terms

  • Bosentan
  • Exercise Test / methods
  • Exercise* / physiology
  • Female
  • Humans
  • Hypertension, Pulmonary / drug therapy*
  • Hypertension, Pulmonary / etiology*
  • Hypertension, Pulmonary / physiopathology
  • Middle Aged
  • Scleroderma, Systemic / complications
  • Scleroderma, Systemic / drug therapy*
  • Scleroderma, Systemic / physiopathology
  • Sulfonamides / therapeutic use*


  • Sulfonamides
  • Bosentan